XVIVO Perfusion files lawsuit against Vivoline

XVIVO Perfusion is suing Vivoline to safeguard XVIVO Perfusion’s exclusive rights to Vivoline’s patents for three products invented by Professor Stig Steen.

XVIVO Perfusion AB (publ) has today initiated legal proceedings against Vivoline Medical in order to safeguard the exclusive global unlimited rights that XVIVO Perfusion AB (publ) has to certain media developed by Professor Stig Steen for the evaluation and preservation of organs in connection with transplantation.

XVIVO Perfusion’s own product STEEN Solution™ is not part of the dispute and is protected by a patent which has been granted and is valid until 2021.

Pursuant to the current agreement with Professor Stig Steen and Igelösa Life Science AB (which is the largest owner of Vivoline Medical), XVIVO Perfusion has global unlimited irrevocable exclusive rights to media and related patents for the preservation and evaluation of organs, media which are based on LPD (low potassium dextran), with added calcium, created by Professor Stig Steen.

A number of Vivoline Medical’s products and related patent rights are for media created by Professor Stig Steen for the preservation and evaluation of organs, media which are based on LPD with added calcium. One such patent thus covered by XVIVO Perfusion’s exclusive rights is the patent protecting Vivoline Medical’s planned product SS2, a solution for reconditioning and evaluating lungs before transplantation. Vivoline Medical’s products Heartadex 1 and 2 are protected by patents and patent applications that also are covered by XVIVO Perfusion’s rights, in accordance with the information given in Vivoline Medical’s memorandum from April 2013.

Magnus Nilsson, XVIVO Perfusion’s CEO states: “XVIVO Perfusion takes a serious view of this and will take action against violations of its intellectual property rights. We aim to continue developing and commercializing Professor Stig Steen’s media in the best possible manner in order to create value for patients, customers and shareholders. The initiation of legal proceedings to safeguard XVIVO Perfusion’s exclusive rights to Vivoline Medical’s media developed by Professor Stig Steen is part of this strategy.”

Gothenburg, October 11, 2013
XVIVO Perfusion AB (publ)

For further information please contact:

Christoffer Rosenblad, CFO, tel: 46 31 788 21 59, e-mail: christoffer.rosenblad@xvivoperfusion.com

Xvivo Perfusion is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on October 11, 2013 at 11:50 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

______________________________________________________________________________________________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The Xvivo share is listed on NASDAQ OMX First North and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
______________________________________________________________________________________________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com

Tags: